Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
bamzireotide navoxetan
product7 mentionslast seen Nov 9, 2026
A clinical-stage program in development for neuroendocrine tumors.
Relationships 9
- Perspective Therapeutics, Inc.developsbamzireotide navoxetan99% confidence7 sources
- bamzireotide navoxetanapplies toneuroendocrine tumor treatment99% confidence4 sources
- bamzireotide navoxetanapplies toneuroendocrine tumors99% confidence3 sources
- bamzireotide navoxetandepends onsomatostatin receptor subtype 2 targeting94% confidence1 source
- bamzireotide navoxetancomposed oflead-212 alpha-emitting radioisotope93% confidence1 source
- bamzireotide navoxetanconforms toEuropean orphan medicinal product designation92% confidence1 source
- bamzireotide navoxetandepends onalpha-emitting radioisotope delivery92% confidence1 source
- bamzireotide navoxetandepends onlead-21292% confidence1 source
- bamzireotide navoxetancomposed of212Pb92% confidence1 source
Relationship
Perspective Therapeutics, Inc.developsbamzireotide navoxetan
99% confidence7 supporting mentions
Either name opens that entity’s relationships.
Sources 7
- filingSEC EDGARNov 9, 2026Perspective Therapeutics, Inc. 8-K: Item 2.02: Results of Operations and Financial Condition; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window
- filingSEC EDGARNov 6, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors)
- filingSEC EDGARNov 6, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
the Company's Phase 1/2a clinical trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET)
- filingSEC EDGAROct 23, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Perspective Therapeutics, Inc. (the "Company") issued a press release and posted to its website a presentation announcing updated interim results from its Phase 1/2a clinical trial of [ 212 Pb]VMT-α-NET
- filingSEC EDGAROct 8, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors)
- filingSEC EDGAROct 1, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
- filingSEC EDGARSep 14, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors)